Onkologie. 2020:14(3):117-121 | DOI: 10.36290/xon.2020.023

Primary mediastinal large B-cell lymphoma: the importance of genetic changes

Helena Urbánková, Michaela Vatolíková, Vít Procházka
Hemato-onkologická klinika Lékařské fakulty Univerzity Palackého a Fakultní nemocnice Olomouc

Primary mediastinal large B-cell lymphoma is a separate entity defined by clinical, histopathological and molecular biological parameters. It represents a subgroup of diffuse large B-cell lymphomas that requires a specific treatment approach. Recurrent genetic changes characteristic for this disease are described. The most common acquired aberrations include point mutations, structural rearrangements and numerical changes in the PDL1, PDL2, CIITA, JAK2 and REL genes. This results in deregulation of NF-κB and JAK / STAT signaling pathways, which play a role in the regulation of gene expression, cell cycle and apoptosis, and changes in surface antigens that affect a cross-talk between immune cells. The need for diagnostic techniques applicable in routine laboratories to distinguish this disease from other large B-cell lymphomas is obvious. In addition to prognostic significance, genetic aberrations may also have a predictive value in newly diagnosed lymphoma of this type, but also in relapse/progression of the disease and could become new therapeutic targets in the future.

Keywords: primary mediastinal large B-cell lymphoma, molecular genetic changes, CIITA, PDL1, PDL2, JAK2.

Published: June 2, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Urbánková H, Vatolíková M, Procházka V. Primary mediastinal large B-cell lymphoma: the importance of genetic changes. Onkologie. 2020;14(3):117-121. doi: 10.36290/xon.2020.023.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011; 117(19): 5019-5032. Go to original source... Go to PubMed...
    2. Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med 2018; 24(5): 679-690. Go to original source... Go to PubMed...
    3. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th Edition. Lyon: International Agency for Research on Cancer (IARC); 2017: 216-221 p.
    4. Rosenwald A, Staudt LM. Gene expression profiling of diffuse large B-cell lymphoma. Leuk Lymphoma 2003; 44(Suppl 3): S41-47. Go to original source... Go to PubMed...
    5. Manso BA, Wenzl K, Asmann YW, Maurer MJ, Manske M, Yang ZZ, et al. Whole-exome analysis reveals novel somatic genomic alterations associated with cell of origin in diffuse large B-cell lymphoma. Blood Cancer J 2017; 7(4): e553. Go to original source... Go to PubMed...
    6. Dunleavy K, Pittaluga S, Maeda LS, Advani R, Chen CC, Hessler J, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 2013; 368(15): 1408-1416. Go to original source... Go to PubMed...
    7. Woessmann W, Lisfeld J, Burkhardt B, Group N-BS. Therapy in primary mediastinal B-cell lymphoma. N Engl J Med 2013; 369(3): 282. Go to original source...
    8. Belada D, Trněný M, et al. Diagnostické a léčebné postupy u nemocných s maligními lymfomy. X. vydání, Belada D, Trněný M, editors. Hradec Králové: HK CREDIT s.r.o.; srpen 2018: 266 p.
    9. Chapuy B, Stewart C, Dunford AJ, Kim J, Wienand K, Kamburov A, et al. Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade. Blood 2019; 134(26): 2369-2382. Go to original source... Go to PubMed...
    10. Ansell SM, Minnema MC, Johnson P, Timmerman JM, Armand P, Shipp MA, et al. Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study. J Clin Oncol 2019; 37(6): 481-489. Go to original source... Go to PubMed...
    11. Armand P, Rodig S, Melnichenko V, Thieblemont C, Bouabdallah K, Tumyan G, et al. Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. J Clin Oncol 2019; 37(34): 3291-3299. Go to original source... Go to PubMed...
    12. Mottok A, Hung SS, Chavez EA, Woolcock B, Telenius A, Chong LC, et al. Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma. Blood 2019; 134(10): 802-813. Go to original source... Go to PubMed...
    13. Kim SJ, Yoon DH, Kang HJ, Hong JY, Lee HS, Oh SY, et al. Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma. BMC Cancer 2019; 19(1): 1080. Go to original source... Go to PubMed...
    14. Lees C, Keane C, Gandhi MK, Gunawardana J. Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions. Br J Haematol 2019; 185(1): 25-41. Go to original source... Go to PubMed...
    15. Scarpa A, Moore PS, Rigaud G, Inghirami G, Montresor M, Menegazzi M, et al. Molecular features of primary mediastinal B-cell lymphoma: involvement of p16INK4A, p53 and c-myc. Br J Haematol 1999; 107(1): 106-113. Go to original source... Go to PubMed...
    16. Tsang P, Cesarman E, Chadburn A, Liu YF, Knowles DM. Molecular characterization of primary mediastinal B cell lymphoma. Am J Pathol 1996; 148(6): 2017-2025.
    17. Savage KJ, Monti S, Kutok JL, Cattoretti G, Neuberg D, De Leval L, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003; 102(12): 3871-3879. Go to original source... Go to PubMed...
    18. Wessendorf S, Barth TF, Viardot A, Mueller A, Kestler HA, Kohlhammer H, et al. Further delineation of chromosomal consensus regions in primary mediastinal B-cell lymphomas: an analysis of 37 tumor samples using high-resolution genomic profiling (array-CGH). Leukemia 2007; 21(12): 2463-2469. Go to original source... Go to PubMed...
    19. Mottok A, Woolcock B, Chan FC, Tong KM, Chong L, Farinha P, et al. Genomic Alterations in CIITA Are Frequent in Primary Mediastinal Large B Cell Lymphoma and Are Associated with Diminished MHC Class II Expression. Cell Rep 2015; 13(7): 1418-1431. Go to original source... Go to PubMed...
    20. Steidl C, Shah SP, Woolcock BW, Rui L, Kawahara M, Farinha P, et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 2011; 471(7338): 377-381. Go to original source... Go to PubMed...
    21. Twa DD, Chan FC, Ben-Neriah S, Woolcock BW, Mottok A, Tan KL, et al. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood 2014; 123(13): 2062-2065. Go to original source... Go to PubMed...
    22. Bentz M, Barth TF, Bruderlein S, Bock D, Schwerer MJ, Baudis M, et al. Gain of chromosome arm 9p is characteristic of primary mediastinal B-cell lymphoma (MBL): comprehensive molecular cytogenetic analysis and presentation of a novel MBL cell line. Genes Chromosomes Cancer 2001; 30(4): 393-401. Go to original source...
    23. Joos S, Otano-Joos MI, Ziegler S, Bruderlein S, du Manoir S, Bentz M, et al. Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene. Blood 1996; 87(4): 1571-1578. Go to original source...
    24. Shi M, Roemer MG, Chapuy B, Liao X, Sun H, Pinkus GS, et al. Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain. Am J Surg Pathol 2014; 38(12): 1715-1723. Go to original source... Go to PubMed...
    25. Wang Y, Wenzl K, Manske MK, Asmann YW, Sarangi V, Greipp PT, et al. Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma. Blood Cancer J 2019; 9(9): 73. Go to original source... Go to PubMed...
    26. Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O'Donnell E, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 2010; 116(17): 3268-3277. Go to original source... Go to PubMed...
    27. Feuerhake F, Kutok JL, Monti S, Chen W, LaCasce AS, Cattoretti G, et al. NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood 2005; 106(4): 1392-1399. Go to original source... Go to PubMed...
    28. Dubois S, Viailly PJ, Mareschal S, Bohers E, Bertrand P, Ruminy P, et al. Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study. Clin Cancer Res 2016; 22(12): 2919-2928. Go to original source... Go to PubMed...
    29. Schmitz R, Hansmann ML, Bohle V, Martin-Subero JI, Hartmann S, Mechtersheimer G, et al. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp Med 2009; 206(5): 981-989. Go to original source... Go to PubMed...
    30. Hinz M, Loser P, Mathas S, Krappmann D, Dorken B, Scheidereit C. Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells. Blood 2001; 97(9): 2798-807. Go to original source... Go to PubMed...
    31. Weniger MA, Gesk S, Ehrlich S, Martin-Subero JI, Dyer MJ, Siebert R, et al. Gains of REL in primary mediastinal B-cell lymphoma coincide with nuclear accumulation of REL protein. Genes Chromosomes Cancer 2007; 46(4): 406-415. Go to original source... Go to PubMed...
    32. Bea S, Zettl A, Wright G, Salaverria I, Jehn P, Moreno V, et al. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood 2005; 106(9): 3183-3190. Go to original source... Go to PubMed...
    33. Rodig SJ, Savage KJ, LaCasce AS, Weng AP, Harris NL, Shipp MA, et al. Expression of TRAF1 and nuclear c-Rel distinguishes primary mediastinal large cell lymphoma from other types of diffuse large B-cell lymphoma. Am J Surg Pathol 2007; 31(1): 106-12. Go to original source... Go to PubMed...
    34. Weniger MA, Melzner I, Menz CK, Wegener S, Bucur AJ, Dorsch K, et al. Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene 2006; 25(18): 2679-84. Go to original source... Go to PubMed...
    35. Melzner I, Bucur AJ, Bruderlein S, Dorsch K, Hasel C, Barth TF, et al. Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line. Blood 2005; 105(6): 2535-42. Go to original source... Go to PubMed...
    36. Steidl C, Gascoyne RD. The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood 2011; 118(10): 2659-69. Go to original source... Go to PubMed...
    37. Ritz O, Guiter C, Castellano F, Dorsch K, Melzner J, Jais JP, et al. Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma. Blood 2009; 114(6): 1236-42. Go to original source... Go to PubMed...
    38. Gunawardana J, Chan FC, Telenius A, Woolcock B, Kridel R, Tan KL, et al. Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma. Nat Genet 2014; 46(4): 329-35. Go to original source... Go to PubMed...
    39. Leroy K, Pujals A, Pelletier L. Targeting STAT6 in PMBL. Oncotarget 2014; 5(17): 7216. Go to original source... Go to PubMed...
    40. Malpeli G, Barbi S, Moore PS, Scardoni M, Chilosi M, Scarpa A, et al. Primary mediastinal B-cell lymphoma: hypermutation of the BCL6 gene targets motifs different from those in diffuse large B-cell and follicular lymphomas. Haematologica 2004; 89(9): 1091-1099. Go to PubMed...
    41. Spina V, Bruscaggin A, Cuccaro A, Martini M, Di Trani M, Forestieri G, et al. Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. Blood 2018; 131(22): 2413-2425. Go to original source... Go to PubMed...
    42. Scott DW, Wright GW, Williams PM, Lih CJ, Walsh W, Jaffe ES, et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood 2014; 123(8) :1214-7. Go to original source... Go to PubMed...
    43. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103(1): 275-82. Go to original source... Go to PubMed...
    44. Lossos IS, Czerwinski DK, Alizadeh AA, Wechser MA, Tibshirani R, Botstein D, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 2004; 350(18): 1828-1837. Go to original source... Go to PubMed...
    45. Wang Z, Cook JR. PDCD1LG2 (PD-L2) RNA in situ hybridization is a sensitive, specific, and practical marker of primary mediastinal large B-cell lymphoma. Br J Haematol 2018; 181(4): 564-566. Go to original source... Go to PubMed...
    46. Mottok A, Wright G, Rosenwald A, Ott G, Ramsower C, Campo E, et al. Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens. Blood 2018; 132(22): 2401-2405. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.